Literature DB >> 1349434

Differential localization of alpha 2-adrenergic receptor subtypes in brain.

J K Wamsley1, M E Alburges, M A Hunt, D B Bylund.   

Abstract

The pharmacological identification and characterization of subtypes of alpha 2-adrenergic receptors have been confirmed by molecular biological investigations. Using receptor autoradiographic techniques, it has been possible to show regions of the brain where alpha 2 agonist binding ([3H]para-aminoclonidine) is preferentially labeling the presumed guaninenucleotide-sensitive, high-affinity conformations of the alpha 2 receptor. Careful examination of autoradiograms generated using the tritiated antagonists yohimbine, idazoxan, and rauwolscine also indicates some disparity in the regions occupied by these radiolabeled ligands. Inhibition of [3H]rauwolscine binding with the subtype selective compounds, ARC-239, or oxymetazoline demonstrates that there are discrete regions of the brain where one receptor subtype predominates over the other. These studies indicate that previous investigations utilizing the agonist para-aminoclonidine as the ligand for obtaining labeling of alpha 2 receptors have overlooked some regions of binding due to the subtype selectivity of this ligand. A more complete localization of alpha 2-adrenergic receptors can be obtained using the tritiated antagonist rauwolscine, and the differential distribution of at least two subtypes of the alpha 2 receptor can be obtained by selective inhibition of this binding.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1349434     DOI: 10.1016/0091-3057(92)90097-y

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  6 in total

1.  Neuron specific alpha-adrenergic receptor expression in human cerebellum: implications for emerging cerebellar roles in neurologic disease.

Authors:  U B Schambra; G B Mackensen; M Stafford-Smith; D E Haines; D A Schwinn
Journal:  Neuroscience       Date:  2005       Impact factor: 3.590

2.  Effect of noradrenergic system on the anxiolytic-like effect of DOI (5-HT2A/2C agonists) in the four-plate test.

Authors:  Fabienne Massé; Martine Hascoët; Eric Dailly; Michel Bourin
Journal:  Psychopharmacology (Berl)       Date:  2005-11-24       Impact factor: 4.530

3.  Changes in postnatal norepinephrine alter alpha-2 adrenergic receptor development.

Authors:  J D Sanders; H K Happe; D B Bylund; L C Murrin
Journal:  Neuroscience       Date:  2011-06-22       Impact factor: 3.590

4.  Distribution of alpha 2-adrenergic binding sites in the parabrachial complex of the rat.

Authors:  H Herbert; G Flügge
Journal:  Anat Embryol (Berl)       Date:  1995-12

5.  A re-evaluation of the role of alpha 2-adrenoceptors in the anxiogenic effects of yohimbine, using the selective antagonist delequamine in the rat.

Authors:  W S Redfern; A Williams
Journal:  Br J Pharmacol       Date:  1995-10       Impact factor: 8.739

6.  Antisense technology reveals the alpha2A adrenoceptor to be the subtype mediating the hypnotic response to the highly selective agonist, dexmedetomidine, in the locus coeruleus of the rat.

Authors:  T Mizobe; K Maghsoudi; K Sitwala; G Tianzhi; J Ou; M Maze
Journal:  J Clin Invest       Date:  1996-09-01       Impact factor: 14.808

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.